Advertisement

 

 

[Stereotactic body radiotherapy of liver metastasis: early experience].

[Stereotactic body radiotherapy of liver metastasis: early experience].
Author Information (click to view)

Földi G, Polgár C, Zongor Z, Melles-Bencsik B, Stelczer G, Madaras B, Pintér T, Jederán É, Lövey J,


Földi G, Polgár C, Zongor Z, Melles-Bencsik B, Stelczer G, Madaras B, Pintér T, Jederán É, Lövey J, (click to view)

Földi G, Polgár C, Zongor Z, Melles-Bencsik B, Stelczer G, Madaras B, Pintér T, Jederán É, Lövey J,

Advertisement

Magyar onkologia 2018 01 3162(1) 62-67

Abstract

Recently the prevalence of oligometastatic patients is increasing. A common site of distant spread is the liver. The standard of care is curative surgical resection, however, the resecability rate is only 10-20%. Alternatively, radiofrequency ablation (RFA) or transarterial chemoembolization (TACE) may be used. Stereotactic ablative body radiotherapy (SABRT) makes it possible to deliver curative radiation dose without radiation injury to the healthy liver tissue. We delivered SABRT to three patients with inoperable hepatic metastases. The primary tumors were rectal (2) and lung (1). The dose was 3×20 Gy every other day. We observed one grade 1 side effect. All the metastases showed complete remission and no local recurrence or late side effect occurred during the one year of follow-up. One patient is tumor-free, one has stable disease, in one patient two new hepatic metastases appeared and receives chemo-biological therapy. SABRT of liver metastases is safe and highly effective. It can be expected that in the near future it will become one of the standard treatments of hepatic tumors.

Submit a Comment

Your email address will not be published. Required fields are marked *

5 × 5 =

[ HIDE/SHOW ]